TP53 and cancer: Given that MDM2 is the major E3 ubiquitin ligase that dictates the p53 level in cells, a better understanding of how MDM2 catalyzes the transfer of ubiquitin would provide the ground for the development of novel strategies for therapeutic activation of p53 in cancer.